NASDAQ · VEEV
Healthcare · Medical - Healthcare Information Services
$260.21
Down-$3.54 (-1.34%)
Updated Sep 20, 2026, 2:59 PM
SID Score
6.8/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
VEEV closed at $260.21 after 19 trading sessions, up 4.73% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $263.40 | $263.745 | $259.09 | $260.21 | 6M |
| Sep 17, 2026 | $263.44 | $266.71 | $260.45 | $263.75 | 1.12M |
| Sep 16, 2026 | $265.27 | $267.96 | $262.44 | $264.90 | 1.11M |
| Sep 15, 2026 | $260.80 | $272.3899 | $258.01 | $266.62 | 1.35M |
| Sep 14, 2026 | $264.93 | $267.4233 | $260.56 | $265.67 | 1.36M |
| Sep 11, 2026 | $261.81 | $263.69 | $259.54 | $262.40 | 863.8K |
| Sep 10, 2026 | $260.99 | $264.58 | $258.1902 | $260.98 | 853.39K |
| Sep 9, 2026 | $266.21 | $266.21 | $259.50 | $260.80 | 1.08M |
| Sep 8, 2026 | $271.62 | $271.65 | $263.91 | $264.84 | 1.47M |
| Sep 4, 2026 | $279.56 | $279.86 | $273.61 | $275.09 | 1.15M |
| Sep 3, 2026 | $284.01 | $288.375 | $277.85 | $284.38 | 1.51M |
| Sep 2, 2026 | $278.28 | $282.43 | $276.05 | $280.72 | 1.49M |
| Sep 1, 2026 | $282.12 | $286.79 | $278.03 | $279.23 | 1.22M |
| Aug 31, 2026 | $274.79 | $290.47 | $273.60 | $285.69 | 2.85M |
| Aug 28, 2026 | $280.00 | $284.68 | $276.45 | $276.69 | 3.64M |
| Aug 27, 2026 | $275.355 | $296.24 | $274.81 | $282.13 | 6.41M |
| Aug 26, 2026 | $239.87 | $247.70 | $238.93 | $244.91 | 1.46M |
| Aug 25, 2026 | $244.27 | $247.85 | $242.53 | $246.78 | 1.62M |
| Aug 24, 2026 | $247.06 | $249.24 | $242.03 | $248.46 | 1.57M |
The latest Smart Investors Daily articles mentioning VEEV.
VEEV research
Company profile and research snapshot.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Citigroup | Neutral | — |
| Aug 27, 2026 | UBS | Neutral | — |
| Aug 27, 2026 | Barclays | Overweight | — |
| Aug 27, 2026 | TD Cowen | Buy | — |
| Aug 27, 2026 | Canaccord Genuity | Hold | — |
No generated briefing is available yet.
Yahoo · Sep 17, 2026
Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ChartMill · Sep 16, 2026
VEEV pairs strong growth, elite profitability, and a debt-free balance sheet with a constructive technical setup, though rich valuation remains a risk.
Yahoo · Sep 15, 2026
What a fantastic six months it’s been for Veeva Systems. Shares of the company have skyrocketed 43%, hitting $265. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Yahoo · Sep 15, 2026
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VEEV.
